Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...

Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, ...

Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to ...

In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...

BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Kenvue shares jumped premarket after The Wall Street Journal reported that Starboard Value has taken a sizable stake in the ...

Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.

Kenvue spun off from Johnson & Johnson (JNJ) in 2023. To watch more expert insights and analysis on the latest market action, ...

Shares in American consumer health products group Kenvue were surging on Monday morning on reports that activist investor ...